Antibody (3)
Launched (3)
Mouse (3)
- (3)
Unconjugated (1)HRP Labeled (1)Biotin-labeled (1)
| Cat. No. | Species | Host | Product Description | Structure | Purity | Feature |
|---|---|---|---|---|---|---|
HOT DXD-M684 | HEK293 | Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 | ||||
DXD-BVM807 | HEK293 | Biotinylated Anti-DXD&Exatecan Antibody, Mouse IgG1, Avitag™ | ||||
DXD-PLM684 | HEK293 | HRP conjugated Monoclonal Anti-DXD&Exatecan Antibody, Mouse IgG1 |
| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Tifcemalimab | TAB-004; JS-004 | Phase 3 Clinical | Shanghai Junshi Biosciences Co Ltd | Solid tumours; Head and Neck Neoplasms; Carcinoma, Renal Cell; Squamous Cell Carcinoma of Head and Neck; Carcinoma, Transitional Cell; Small Cell Lung Carcinoma; Pancreatic Neoplasms; Hodgkin Disease; Nasopharyngeal Carcinoma; Lymphoma; Lung Neoplasms; Melanoma; Neoplasm Metastasis | Details |
| ANB-032 | ANB-032 | Phase 2 Clinical | Anaptysbio Inc | Inflammation; Dermatitis, Atopic; Eczema | Details |
| Venanprubart | LY-3361237 | Phase 2 Clinical | Sanford-Burnham Medical Research Institute, Eli Lilly And Company | Sjogren's Syndrome; Lupus Erythematosus, Systemic; Psoriasis | Details |
| MB-272 | MB272; GS-0272 | Phase 1 Clinical | University Of Oxford | Arthritis, Rheumatoid; Autoimmune Diseases; Lupus Erythematosus, Systemic | Details |
| HFB-200603 | HFB-200603 | Phase 1 Clinical | HiFiBiO Therapeutics | Carcinoma, Renal Cell; Stomach Neoplasms; Neoplasms; Colorectal Neoplasms; Melanoma; Carcinoma, Non-Small-Cell Lung | Details |

[North America]: +1 800-810-0816
[Switzerland]: +41 800 040 012
[Asia & Pacific]: +86 400-682-2521
[North America]: 1 Innovation Way, Newark, DE 19711, USA
[Switzerland]: ACRObiosystems AG, c/o Zug Dammstrasse Centre AG, Dammstrasse 19, 6300 Zug Switzerland



